International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

@article{Farge2013InternationalCP,
  title={International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer},
  author={Dominique Farge and P. Debourdeau and Marielle M J Beckers and Caroline Baglin and Rupert M Bauersachs and Benjamin Brenner and Dialina Brilhante and Anna Falanga and G T Gerotzafias and Nissim Haim and Ajay K Kakkar and Alok A. Khorana and Ram{\'o}n Lecumberri and Mario Mandal{\`a} and Michel Marty and Manuel Monreal and Shaker A. Mousa and Simon Noble and Ingrid Pabinger and Paolo Prandoni and Martin H. Prins and Mohammed Hassan Qari and Michael B. Streiff and Konstantinos N Syrigos and Henri Bounameaux and Harry R B{\"u}ller},
  journal={Journal of Thrombosis and Haemostasis},
  year={2013},
  volume={11}
}
Summary.  Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide. Objectives: To establish a common international consensus addressing practical, clinically relevant questions in this setting. Methods: An international consensus working group of experts was set up to develop guidelines according to an evidence‐based medicine approach, using the GRADE system. Results: For the… Expand
Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline
TLDR
This clinical practice guideline to assist health care providers in evidence-based clinical decision-making for VTE prophylaxis and treatment in patients with cancer is produced. Expand
Guidelines for the management of cancer and thrombosis - Special aspects in women.
TLDR
There is insufficient guidance on many women specific aspects commonly encountered during clinical practice of venous thromboembolism in cancer patients, and there are no guideline recommendations for women specific cancer types or women specific issues in the prevention and treatment of VTE. Expand
Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study.
TLDR
Adhesion to national guidelines for treatment of venous thromboembolism in cancer is not optimal, underlying the need for further education to achieve a better implementation on a national level. Expand
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer.
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at an increased risk of developing VTE and are more likely to have a recurrence of VTEExpand
What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?
TLDR
Evidence favoring an impact of LMWH on survival in cancer patients is weak and the novel oral anticoagulants should be investigated more carefully before being routinely implemented in the treatment of cancer-associated VTE. Expand
Practice Patterns for Prophylaxis and Treatment of Venous Thromboembolism in German Cancer Patients
TLDR
It is revealed that practice patterns often do not follow the guideline recommendations with respect to the use of LMWH for long-term treatment of VTE in cancer patients. Expand
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.
TLDR
Prophylaxis in the outpatient, inpatient, and perioperative settings was considered, as were treatment and use of anticoagulation as a cancer-directed therapy in patients with cancer. Expand
Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC).
TLDR
The 2019 ITAC-CME evidence-based CPGs for treatment and prophylaxis of cancer-related VTE are summarized, which include recommendations on the use of direct oral anticoagulants specifically in cancer patients. Expand
Clinical practice guidelines for prophylaxis of venous thomboembolism in cancer patients.
TLDR
If thromboprophylaxis is warranted in cancer patients undergoing surgery or hospitalised for acute medical illness or with a lower mobility in the absence of contraindications to anticoagulants, its benefit remains controversial in outpatients and may be limited to locally advanced or metastatic pancreatic or lung cancer treated with chemotherapy. Expand
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
TLDR
The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 182 REFERENCES
2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group.
TLDR
The treatment of VTE in patients with cancer, including those with intracranial malignancies, should be based on low-molecular-weight heparins administered at therapeutic doses for at least 3 months, according to guidelines established according to the SOR methodology. Expand
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
TLDR
LMWH is possibly superior to UFH in the initial treatment of VTE in patients with cancer and the overall quality of evidence was low for LMWH versus UFH due to imprecision and likely publication bias. Expand
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
TLDR
LMWH is possibly superior to UFH in the initial treatment of VTE in patients with cancer and the overall quality of evidence was low for LMWH versus UFH due to imprecision and likely publication bias. Expand
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
TLDR
This chapter about treatment for venous thromboembolic disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) and indicates that the benefits do or do not outweigh risks, burden, and costs. Expand
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
TLDR
For the long-term treatment of VTE in patients with cancer, LMWH compared with VKA reduces venous thromboembolic events but not mortality, and the quality of evidence is judged as low for mortality, major bleeding, and minor bleeding; and as moderate for recurrent VTE. Expand
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical PracticeExpand
Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis.
TLDR
A comprehensive review of anticoagulation treatment in patients with cancer, with particular focus on studies that included patients with advanced disease, suggests long-term full-dose low-molecular-weight heparin (LMWH) is more effective than warfarin in the secondary prophylaxis of venous thromboembolism. Expand
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
  • G. Lyman, A. Khorana, +13 authors C. Francis
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
Recommendations were developed on the prevention of VTE in hospitalized, ambulatory, and surgical cancer patients as well as patients with established VTE, and for use of anticoagulants in cancer patients without VTE to improve survival. Expand
Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants
TLDR
Evaluating the efficacy and safety of long‐term treatment of VTE with LMWH compared with OA indicates that a 3‐month course of LMWH is as effective and safe as a corresponding period of OA treatment, and may thus be considered as a valuable alternative option for patients in whom OAtreatment appears contraindicated or problematic. Expand
Prevention of venous thromboembolism in neurosurgery: a metaanalysis.
TLDR
In a mixed neurosurgical population, LMWH and ICDs are both effective in the prevention of VTE, and isolated high-risk groups may benefit from a combination of prophylactic methods, suggesting the need for a more individualized approach to these patients. Expand
...
1
2
3
4
5
...